BidaskClub cut shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from a hold rating to a sell rating in a report released on Friday.
TTPH has been the topic of a number of other research reports. HC Wainwright restated a buy rating and set a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, December 5th. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, October 28th. Finally, ValuEngine lowered Tetraphase Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $15.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $5.19 on Friday. The firm has a market capitalization of $266.84, a price-to-earnings ratio of -1.81 and a beta of 2.28. Tetraphase Pharmaceuticals has a 52-week low of $3.65 and a 52-week high of $9.93.
In related news, Director L Patrick Gage bought 3,880 shares of the business’s stock in a transaction on Wednesday, November 29th. The shares were purchased at an average cost of $6.45 per share, with a total value of $25,026.00. Following the acquisition, the director now owns 38,880 shares of the company’s stock, valued at $250,776. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider Jacques Dumas sold 7,167 shares of Tetraphase Pharmaceuticals stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $6.21, for a total value of $44,507.07. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in TTPH. SG Americas Securities LLC acquired a new position in Tetraphase Pharmaceuticals during the 3rd quarter worth about $107,000. Brighton Jones LLC acquired a new position in Tetraphase Pharmaceuticals during the 3rd quarter worth about $108,000. Virtu KCG Holdings LLC acquired a new position in Tetraphase Pharmaceuticals during the 2nd quarter worth about $147,000. Voya Investment Management LLC lifted its holdings in Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 3,104 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in Tetraphase Pharmaceuticals during the 2nd quarter worth about $162,000. 58.36% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals (TTPH) Downgraded by BidaskClub” was published by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.thestockobserver.com/2018/02/06/tetraphase-pharmaceuticals-ttph-downgraded-by-bidaskclub.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.